Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Herpes simplex Infection

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 18 articles:
HTML format



Single Articles


    April 2021
  1. CARR DJJ, Berube AN, Filiberti A, Gmyrek GB, et al
    Lack of neonatal Fc receptor does not diminish the efficacy of the HSV-1 0DeltaNLS vaccine against ocular HSV-1 challenge.
    Vaccine. 2021 Apr 1. pii: S0264-410X(21)00379.
    PubMed     Abstract available


    October 2020
  2. LATOURETTE PC 2ND, Awasthi S, Desmond A, Pardi N, et al
    Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine.
    Vaccine. 2020 Oct 8. pii: S0264-410X(20)31261.
    PubMed     Abstract available


    October 2019
  3. BERNSTEIN DI, Morello CS, Cardin RD, Bravo FJ, et al
    A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2.
    Vaccine. 2019 Oct 11. pii: S0264-410X(19)31332.
    PubMed     Abstract available


    September 2019
  4. BERNSTEIN DI, Cardin RD, Bravo FJ, Hamouda T, et al
    Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes.
    Vaccine. 2019 Sep 9. pii: S0264-410X(19)31153.
    PubMed     Abstract available


    May 2019
  5. AWASTHI S, Hook LM, Swaminathan G, Cairns TM, et al
    Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants.
    Vaccine. 2019 May 29. pii: S0264-410X(19)30705.
    PubMed     Abstract available


  6. BERNSTEIN DI, Flechtner JB, McNeil LK, Heineman T, et al
    Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.
    Vaccine. 2019 May 15. pii: S0264-410X(19)30621.
    PubMed     Abstract available


    December 2018
  7. HOOK LM, Awasthi S, Dubin J, Flechtner J, et al
    A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.
    Vaccine. 2018 Dec 12. pii: S0264-410X(18)31639.
    PubMed     Abstract available


    November 2018
  8. BERNSTEIN DI, Pullum DA, Cardin RD, Bravo FJ, et al
    The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes.
    Vaccine. 2018 Nov 21. pii: S0264-410X(18)31565.
    PubMed     Abstract available


    April 2018
  9. ZHANG X, Jiang Q, Xu X, Wang Y, et al
    Immune mechanisms induced by an HSV-1 mutant strain: Discrepancy analysis of the immune system gene profile in comparison with a wild-type strain.
    Vaccine. 2018;36:2394-2402.
    PubMed     Abstract available


  10. STANFIELD BA, Rider PJF, Caskey J, Del Piero F, et al
    Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses.
    Vaccine. 2018 Apr 11. pii: S0264-410X(18)30444.
    PubMed     Abstract available


  11. SPICKNALL IH, Looker KJ, Gottlieb SL, Chesson HW, et al
    Review of mathematical models of HSV-2 vaccination: Implications for vaccine development.
    Vaccine. 2018 Apr 3. pii: S0264-410X(18)30254.
    PubMed     Abstract available


    December 2017
  12. GOTTLIEB SL, Giersing BK, Hickling J, Jones R, et al
    Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.
    Vaccine. 2017 Dec 7. pii: S0264-410X(17)31492.
    PubMed     Abstract available


    September 2017
  13. SCHIFFER JT, Gottlieb SL
    Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.
    Vaccine. 2017 Sep 25. pii: S0264-410X(17)31273.
    PubMed     Abstract available


    June 2017
  14. GOTTLIEB SL, Giersing B, Boily MC, Chesson H, et al
    Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Vaccine. 2017 Jun 21. pii: S0264-410X(17)30408.
    PubMed     Abstract available


  15. ACHDOUT H, Lustig S, Israely T, Erez N, et al
    Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models.
    Vaccine. 2017 Jun 20. pii: S0264-410X(17)30791.
    PubMed     Abstract available


    September 2016
  16. FLECHTNER JB, Long D, Larson S, Clemens V, et al
    Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.
    Vaccine. 2016 Sep 15. pii: S0264-410X(16)30795.
    PubMed     Abstract available


    March 2016
  17. NICOLI F, Gallerani E, Skarlis C, Sicurella M, et al
    Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection.
    Vaccine. 2016 Mar 18. pii: S0264-410X(16)00333.
    PubMed     Abstract available


    November 2015
  18. ODEGARD JM, Flynn PA, Campbell DJ, Robbins SH, et al
    A novel HSV-2 subunit vaccine induces GLA-dependent CD4 and CD8 T cell responses and protective immunity in mice and guinea pigs.
    Vaccine. 2015 Nov 10. pii: S0264-410X(15)01600.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Herpes simplex Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: